Company intelligence / Profile preview

Gyre Therapeutics

San Diego, California, United Statesgyretx.com ↗

Ownership: Public · GYRE
Development stage: Phase 3

Overview

Gyre Therapeutics is advancing multiple clinical programs, with a pivotal Phase 3 trial for Hydronidone in CHB-associated liver fibrosis expected to report data in Q2 2025. The company is also planning a Phase 2 trial of Hydronidone for MASH-associated liver fibrosis in the US in 2025. Their commercial portfolio in China includes pirfenidone for IPF and plans to launch nintedanib and avatrombopag in 2025.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularRheumatologyNephrologyImmunologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

dalcinonacog alfa

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $751.4M
Total revenue: $29.1M
Enterprise value: $680.1M

Beyond the preview

Go deeper on Gyre Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gyre Therapeutics.

Explore the full profile